Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy.

Core tip: Oral dichloroacetate sodium (DCA) has been investigated as a novel metabolic therapy for various cancers. Response to therapy in human studies is measured by standard RECIST definitions, which define “response” by the degree of tumour reduction, or tumour disappearance on imaging. However, DCA can also act as a cytostatic agent, without causing apoptosis (programmed cell death). A case is presented in which oral DCA therapy resulted in tumour stabilization of stage 4 colon cancer in a 57 years old female for a period of nearly 4 years, with no serious toxicity.

INTRODUCTION

The drug sodium dichloroacetate (DCA) has been investigated as a novel metabolic therapy for various cancers since 2007 when Bonnet et al[ 1 ] published a combined in vitro/in vivo rat study demonstrating the efficacy of DCA in treating human lung, breast and brain cancers by inhibition of mitochondrial pyruvate dehydrogenase kinase. Stacpoole et al[ 2 - 4 ] had previously published multiple studies involving DCA for the treatment of congenital lactic acidosis, which is composed of a collection of inherited mitochondrial diseases[ 5 ]. These studies established the safety profile of oral DCA in humans. DCA was discovered to be a safe drug with no cardiac, pulmonary, renal or bone marrow toxicity[ 4 ]. The most serious common side effect consists of peripheral neuropathy, which is reversible[ 6 ]. Delirium has been reported, and is reversible after discontinuation of DCA[ 7 ]. Asymptomatic and reversible liver enzyme elevation has been reported in a small percentage of patients[ 3 ]. The prior work in congenital lactic acidosis has enabled the rapid progression of DCA into the cancer clinic. Four reports have now been published of cancer clinical trials using DCA, indicating a growing recognition of the potential usefulness of DCA[ 8 - 11 ]. However, these trials treating late stage patients, have only been able to report on treatment for relatively short time periods.

In the initial 2007 paper by Bonnet et al[ 1 ], it was reported that DCA reduced mitochondrial membrane potential resulting in selective apoptosis in cancer cells. The mechanism identified was inhibition of aerobic glycolysis (the Warburg effect) and activation of mitochondrial potassium ion channels[ 1 ]. Further investigation of DCA confirmed anti-cancer activity in several cancer types including colon[ 12 ], prostate[ 13 ], ovarian[ 14 ], neuroblastoma[ 15 ], lung carcinoid[ 16 ], cervical[ 17 ], endometrial[ 18 ], cholangiocarcinoma[ 19 ], sarcoma[ 20 ] and T-cell lymphoma[ 21 ]. Other antineoplastic actions of DCA have also been suggested. These include angiogenesis blockade[ 22 ], changes in expression of HIF1-α[ 23 ], alteration of pH regulators V-ATPase and MCT1, and other cell survival regulators such as PUMA, GLUT1, Bcl2 and p53[ 24 ]. However, in the quest for cytotoxic activity, many in vitro reports use concentrations of DCA that are unlikely to be achieved clinically[ 25 ]. Some studies have used restricted concentrations and found DCA to be cytostatic rather than cytotoxic, but able to enhance apoptosis with other agents[ 26 - 28 ]. In the report of successful in vivo DCA treatment of breast cancer, Sun et al[ 26 ] found DCA to be cytostatic, inhibiting proliferation without increasing apoptosis. DCA was able to significantly reduce metastatic burden in the lungs of rats in a highly metastatic in vivo model of breast cancer. This suggests a new role for DCA as a cancer stabilizing agent, similar to an anti-angiogenic therapy. However, to the authors’ knowledge, no human data has yet been published supporting the use of DCA for long-term maintenance of stable disease.

As a result of Bonnet’s groundbreaking DCA publication, in early 2007, Khan commenced the clinical use of DCA to treat cancer patients with a poor prognosis or who failed to respond to approved cancer therapies. A protocol of natural medications was developed to address the dose-limiting neurologic toxicity, in collaboration with a naturopathic physician (Andrews). The oral DCA regimen that was developed included three natural medications acetyl L-carnitine[ 29 - 31 ], R-alpha lipoic acid[ 32 - 34 ] and benfotiamine[ 35 - 37 ], for the primary purpose of neuropathy prevention. Observational data collected from more than 300 cancer patients with advanced disease revealed measurable benefits from DCA therapy in 60%-70% of cases. The neuropathy risk with inclusion of natural neuroprotective agents was roughly 20% with 20-25 mg/kg per day dosing on a 2 wk on/1 wk off cycle. Reversible liver enzyme elevation was noted in approximately 2% in this patient group (clinic observational data published online at www.medicorcancer.com ).

A patient case illustrating the cytostatic effects of oral DCA treatment maintained over several years is presented. This patient had a poor prognosis (median survival of 9-12 mo for stage 4 colorectal cancer using aggressive conventional palliative chemotherapy)[ 38 ]. The patient was treated by Khan in cooperation with the naturopathic physician Andrews, who developed a protocol comprised of natural neuroprotective agents.

CASE REPORT

A 57 years old female attended the author’s clinic (Khan) in March 2012 seeking therapy for metastatic colorectal cancer. The patient was originally diagnosed with rectal cancer in mid-2010 when she consulted her doctor for new constipation and low back pain. Colonoscopy was attempted, but the colonoscope could not be advanced due to the presence of a partially-obstructing rectal tumour. Biopsy confirmed moderately differentiated colorectal adenocarcinoma. Computerized tomography (CT) scan at the time demonstrated stage 4 disease with multiple liver metastases up to 3 cm in diameter, possible tiny lung metastases and an annular rectal carcinoma that was not easily measured (margins of the cancer were difficult to distinguish from the surrounding tissues on CT scan). The patient underwent a loop ileostomy procedure to bypass the obstruction, and the rectal tumour was not excised. Surgery was followed by chemotherapy consisting of 5-fluorouracil, irinotecan, leucovorin and bevacizumab (FOLFIRI + bevacizumab). Initially the patient responded to chemotherapy with a reduction in liver metastases, a reduction of the primary rectal lesion, and a reduction of blood carcinoembryonic antigen (CEA) marker from 260.9 ng/mL before chemo to 3.5 ng/mL just prior to DCA therapy initiation. The response to chemo then began to plateau. By the time the patient presented to the author’s clinic, chemotherapy was causing minimal disease reduction, and was essentially just maintaining stability.

The patient was previously healthy, and had a 20 year smoking history. She consumed alcohol on occasion. There was a positive family history of colon cancer and gastric cancer. Medications included ongoing chemotherapy as described, hydrogen peroxide enemas, oral vitamin C, occasional oral vitamin D, time-release hydromorphone 32 mg twice a day, and short-acting hydromorphone 2-4 mg orally as needed for “breakthrough” pain. There were no allergies. Functional enquiry revealed some mild mouth sores related to the ongoing chemotherapy, mild diarrhea (expected with an ileostomy) and mild intermittent rectal bleeding. There was aching/burning lower back and sacral pain up to 6 out of 10 intensity, and mild right shoulder-tip pain exacerbated by chemotherapy (felt to be referred pain related to liver metastases).

Since the chemotherapy was still effective, and the patient was not experiencing any serious side effects, the initial approach was to support the patient’s existing therapy, not replace it. An integrative plan was made in cooperation with a naturopathic physician (Andrews). The plan consisted of addition of high dose oral vitamin D at 10000 international units per day, a change of oral vitamin C to vitamin C 50 g intravenous ( i.v .) weekly, and addition of dichloroacetate sodium (DCA) 3000 mg i.v . (49 mg/kg) weekly (manufacturer: Tokyo Chemical Industry, United States). To reduce the risk of DCA side effects, 3 natural supplements were prescribed: Alpha lipoic acid (racemic) 500 mg i.v . with each DCA dose, oral R-alpha lipoic acid 150 mg 3 times a day, oral acetyl L-carnitine 500 mg 3 times a day, and oral benfotiamine 80 mg twice a day. Infusions were planned around chemotherapy infusions (separated by at least 2 d from chemotherapy) to avoid any potential interference or drug interactions. Lipoic acid was not given on chemotherapy days, or within 1 d before or after chemotherapy, since it is a powerful antioxidant and has the potential to reduce chemotherapy efficacy. Integrative therapy began in March 2012. No side effects were noted, so DCA was increased to 4000 mg i.v . (66 mg/kg) weekly. The only side effect noted at the higher DCA dose was mild post-infusion sedation.

Oral metformin was added to help sensitize the cancer to the chemotherapy, starting at 500 mg orally once a day with titration up to 500 mg 3 times a day[ 39 ]. Pregabalin was added to help control the neuropathic sacral pain (started 50 mg daily, titrated up to 50 mg 3 times a day). Chemotherapy side effects included nausea and vomiting (prior to initiation of metformin), and metformin was skipped on days when the patient felt unwell to prevent potential toxicity, should the patient become dehydrated.

Routine baseline blood tests were obtained including complete cell counts, standard metabolic panel, liver enzymes and bilirubin (Table 1 ). A baseline CT scan was available, which had been performed 2 mo prior to initiation of integrative therapy with DCA.

After 4 mo of integrative therapy as described, a new CT scan was performed (Figure 1 ), which was reported as “stable and unchanged”, but no measurements were given. An incidental finding of a gallstone was noted (also stable from prior scan). The patient became frustrated that no improvement was noted, and no detailed measurements were indicated in the CT report. An attempt was made to obtain a positron emission tomography scan to clarify live vs necrotic tumours, but government funding could not be obtained and the patient declined to pay privately for the scan.

After some discussion, the patient elected to continue therapy, and obtain future CT scans at a different hospital. By September 2012, increasing chemotherapy side effects including fatigue, nausea and vomiting were noted. A new CT scan revealed that all the liver lesions were “either smaller or no longer identified”. The greatest tumour reduction was only 2 mm however (2.5 cm marker lesion in liver segment 4a reduced to 2.3 cm). There were no new lesions identified.

After review of the CT scan, the patient decided to stop all chemotherapy, as well as bevacizumab and metformin. DCA i.v . was continued, and the dose was increased to 4500 mg i.v . weekly. Nausea and vomiting resolved. Pain remained under control. A new CT scan was obtained after 3 mo, which demonstrated residual rectal tumour with stricture and proximal fecal loading (unchanged), and “liver metastases, not significantly changed”. The patient reported mild numbness of the fingers and toes. There was a further increase in asymptomatic liver enzyme elevations (Table 2 ). Both of these were diagnosed as DCA side effects. During therapy up to this point, CEA had shown mild fluctuations, but was considered stable overall (Figure 2 ).

DCA therapy was interrupted for 3 mo to allow resolution of DCA side effects. During this time, only natural therapies were given (prescribed by Andrews). Acetyl L-carnitine, benfotiamine and alpha lipoic acid were continued to accelerate recovery of DCA neuropathy. Oral curcumin[ 40 ] and honokiol (magnolia tree extract) were added in an attempt to maintain cancer control[ 41 ]. During the period when DCA was stopped, CEA increased from 4.1 to 5.1 ng/mL (Figure 2 ). Mild DCA neuropathy had resolved and liver enzymes began to improve.

By March 2013, due to concern over the cost of infusion therapy, it was decided to begin oral DCA therapy. A new baseline CT scan demonstrated a 1 mm increase in a liver segment 7 marker lesion, and a 1 mm increase in a marker aortocaval lymph node, but was reported as “stable appearance of the colon” and “stable liver metastases”.

Oral DCA was initiated at a dose of 500 mg (8.2 mg/kg) twice a day, and neuroprotective supplements consisting of oral acetyl L-carnitine, benfotiamine and R-alpha lipoic acid were continued. Supplements were given continuously, and DCA was given on a 2 wk on/1 wk off cycle.

In December 2013, the pain medication was transitioned from hydromorphone to methadone 10 mg 3 times a day, for simplicity, improved pain control and cost savings.

The patient continued on this regimen with regular CT scans every 3 to 6 mo. The patient became less compliant with regular blood testing due to a busy work schedule. She remained highly functional (ECOG level 1) with mild chronic DCA neuropathy that was controlled and did not affect her daily function. An attempt was made to increase DCA to 500 mg 3 times a day, but this resulted in significant asymptomatic liver enzyme elevation and increase in neuropathy. As a result, a DCA dose of 500 mg twice a day was resumed after a brief therapy interruption.

Ongoing CT scans continued to reveal stable disease (Figure 3 ), with no new lesions appearing. Overall CEA was not significantly changed from the initiation of DCA therapy (CEA of 3.5 at the start of DCA therapy, to CEA of 3.7 after nearly 4 years of therapy). General blood panel was also favourable at the 3 year mark (Table 3 ) and after the 4 year mark (Table 4 ).

In summary, after receiving conventional chemotherapy for approximately 18 mo, the patient received intravenous DCA therapy with concurrent chemotherapy for approximately 6 mo, followed by intravenous and oral DCA therapy with no concurrent conventional cancer therapy for nearly 4 years. During the treatment with oral DCA, the patient experienced stable disease by CT scans, and stable disease by CEA tumour marker measurement. She also was clinically stable with no escalation of methadone dose, maintenance of ECOG level 1 function, stable mild DCA neuropathy, and she was able to run her own business successfully.

DISCUSSION

This case of DCA therapy in a patient with advanced stage 4 colon cancer demonstrates long-term stable disease according to clinical, biochemical and radiologic criteria. The duration of stability while on DCA without other active chemotherapy is currently 46 mo (nearly 4 years), with a survival time since the initial diagnosis of stage 4 colorectal cancer of 6 years. Based on the National Cancer Institute’s SEER cancer statistics review 1975-2011, the 5-year relative survival rate for females diagnosed with stage IV colon/rectal cancer was 14.4% ( http://seer.cancer.gov/csr/1975_2013/ ). While it cannot be definitively concluded that DCA has been efficacious, survival for this length of time in the absence of ongoing chemotherapy would be of relatively low probability. Cytostatic rather than cytotoxic effects of DCA on colorectal and other cancer cells have been reported and support this clinical finding[ 23 , 27 , 42 - 44 ]. To date the patient remains clinically well and she remains on DCA therapy.

In addition to the maintenance of stable disease, this case demonstrates the tolerability of oral DCA in a cancer patient for much longer time periods than those currently reported from the published clinical trials in cancer patients. Chu et al[ 11 ] reported on 24 patients treated for a median time of 2 mo at either 6.25 or 12.5 mg/kg BID, on continuous oral DCA without neuroprotective supplements. They concluded that the recommended phase 2 dose was 6.25 mg/kg BID (12.5 mg/kg per day), with careful monitoring of neuropathy being needed. Dunbar et al[ 9 ] recommended 5 mg/kg BID as a starting dose for most patients, with their trial administering 4, 8 or 12.5 mg/kg BID continuously (median time on DCA 34 d), also without neuroprotective supplements. The patient in this report took 500 mg BID, equivalent to 8.2 mg/kg BID, 2 wk on/1 wk off, but could not tolerate this dose three times a day (total of 25 mg/kg per day). Dunbar et al[ 9 ] suggest that genotyping for polymorphisms in GSTZ1 , the DCA metabolizing enzyme in the liver which is inactivated with ongoing DCA usage[ 45 ], should be considered in determining the starting dose for patients. However further work is necessary to gather convincing numbers of genotypes and dose-tolerance data. A clinical trial of DCA in multiple myeloma patients is currently underway to contribute to this pool of data (Australia New Zealand Clinical Trials Register #ACTRN12615000226505, http://www.anzctr.org.au ). Further studies are required to determine the optimal dosage regime for maximum tolerable acute or chronic treatment with DCA, and indeed what dose is required for efficacy.

The case presented indicates DCA holds great promise as a cancer therapy. The patient achieved a significant benefit from her therapy, with mild side effects and no hematological, cardiac, pulmonary or renal toxicity. Some hepatic toxicity was observed (Table 2 ), which was easily managed by DCA therapy interruption followed by dose adjustment. Mild reversible peripheral neurotoxicity was reported. Natural therapies that were combined with DCA (acetyl L-carnitine, alpha lipoic acid and benfotiamine) assisted the patient with reduction of side effects, but are not known to function as cancer therapies.

As of this writing, no active clinical trials exist investigating the human use of DCA as a cytostatic agent. Due to the fact that DCA is off patent, raising adequate funds to support large scale human trials is a serious challenge. It is hoped that this case exemplifying the benefits of oral DCA will stimulate further clinical investigation.

Based on our clinical experience, combined with existing publications, off-label DCA therapy is an option for patients with limited available conventional treatments, once they understand and accept the risks and benefits of therapy. This case report shows that even in advanced stage disease, DCA has the potential to prolong life without impacting a patient’s quality of life, as compared to chemotherapy with its frequent debilitating side effects or compromise in physiological function. Given its reasonable cost and modest toxicity, DCA deserves further investigation.

ACKNOWLEDGMENTS

The authors wish to thank Dr. Humaira Khan for her assistance, and also the patient for her support and consent to publish her case.

COMMENTS

Case characteristics

The 57 years old female patient presented with constipation and lower back pain.

Clinical diagnosis

The patient was diagnosed with a partially-obstructing rectal cancer.

Laboratory diagnosis

Elevated carcinoembryonic antigen tumour marker.

Imaging diagnosis

Rectal mass seen on colonoscopy.

Pathological diagnosis

Moderately differentiated colorectal adenocarcinoma.

Treatment

Loop ileostomy followed by chemotherapy consisting of 5-fluorouracil, irinotecan, leucovorin and bevacizumab, then addition of dichloroacetate sodium (DCA), then DCA without chemo for nearly 4 years.

Related reports

Computerized tomography scan reports demonstrate reduction of cancer with combined chemotherapy + DCA, then stable disease for nearly 4 years with DCA and no chemo.

Term explanation

DCA: Dichloroacetate sodium; RECIST: Response evaluation criteria for solid tumours; ECOG: Eastern cooperative oncology group; SEER: Surveillance, epidemiology and end results.

Experiences and lessons

DCA is not only a pro-apoptotic drug, but may also act as a cytostatic agent, and can thus achieve long-term stabilization of advanced cancer without serious side effects, as illustrated by this rectal cancer case.

Peer-review

DCA, the sodium salt of dichloroacetate, is a cheap chemical compound that has shown some clear potential as an alternative cancer treatment, which has been used in a number of trials with people suffering from brain cancer, or glioblastoma. This is a well-written case report in which oral DCA therapy resulted in tumor stabilization of stage 4 colon cancer in a 57 years old female for a period of over 3 years, with no serious toxicity. This report covers what it promises to. The authors do a solid job of explaining the basics of DCA therapy and its role in different tumor types. Along with the addition of mechanisms of action against cancer cells and therapeutic potential of DCA, the authors provide a good resource for readers who are more unfamiliar with DCA therapy but also provide detail.

Institutional review board statement: Not applicable.

Informed consent statement: The patient described in this manuscript has given consent to publish her case anonymously.

Conflict-of-interest statement: One of the authors (Khan) administers dichloroacetate therapy for cancer patients through Medicor Cancer Centres at a cost, and without profit. The clinic is owned by a family member of this author. The other authors have nothing to disclose.

Manuscript source: Invited manuscript

Specialty Type: Medicine, research and experimental

Country of Origin: Australia

Peer-Review Report Classification

Grade A (Excellent): 0

Grade B (Very good): B,B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

Peer-review started: May 3, 2016

First decision: June 17, 2016

Article in press: August 8, 2016

P- Reviewer: Lakatos PL, Song J, Zhu YL S- Editor: Ji FF L- Editor: A E- Editor: Wu HL

1 Bonnet S Archer SL Allalunis-Turner J Haromy A Beaulieu C Thompson R Lee CT Lopaschuk GD Puttagunta L Bonnet S A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth Cancer Cell 2007 11 37 51 17222789 10.1016/j.ccr.2006.10.020

2 Stacpoole PW Kurtz TL Han Z Langaee T Role of dichloroacetate in the treatment of genetic mitochondrial diseases Adv Drug Deliv Rev 2008 60 1478 1487 18647626 10.1016/j.addr.2008.02.014 PMC3746325

3 Stacpoole PW Gilbert LR Neiberger RE Carney PR Valenstein E Theriaque DW Shuster JJ Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate Pediatrics 2008 121 e1223 e1228 18411236 10.1542/peds.2007-2062 PMC3777225

4 Stacpoole PW Kerr DS Barnes C Bunch ST Carney PR Fennell EM Felitsyn NM Gilmore RL Greer M Henderson GN Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children Pediatrics 2006 117 1519 1531 16651305 10.1542/peds.2005-1226

5 Berendzen K Theriaque DW Shuster J Stacpoole PW Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency Mitochondrion 2006 6 126 135 16725381 10.1016/j.mito.2006.04.001

6 Kaufmann P Engelstad K Wei Y Jhung S Sano MC Shungu DC Millar WS Hong X Gooch CL Mao X Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial Neurology 2006 66 324 330 16476929 10.1212/01.wnl.0000196641.05913.27

7 Brandsma D Dorlo TP Haanen JH Beijnen JH Boogerd W Severe encephalopathy and polyneuropathy induced by dichloroacetate J Neurol 2010 257 2099 2100 20632025 10.1007/s00415-010-5654-9

8 Michelakis ED Sutendra G Dromparis P Webster L Haromy A Niven E Maguire C Gammer TL Mackey JR Fulton D Metabolic modulation of glioblastoma with dichloroacetate Sci Transl Med 2010 2 31ra34 10.1126/scitranslmed.3000677 20463368

9 Dunbar EM Coats BS Shroads AL Langaee T Lew A Forder JR Shuster JJ Wagner DA Stacpoole PW Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors Invest New Drugs 2014 32 452 464 24297161 10.1007/s10637-013-0047-4 PMC4455946

10 Garon EB Christofk HR Hosmer W Britten CD Bahng A Crabtree MJ Hong CS Kamranpour N Pitts S Kabbinavar F Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer J Cancer Res Clin Oncol 2014 140 443 452 24442098 10.1007/s00432-014-1583-9 PMC3939783

11 Chu QS Sangha R Spratlin J Vos LJ Mackey JR McEwan AJ Venner P Michelakis ED A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors Invest New Drugs 2015 33 603 610 25762000 10.1007/s10637-015-0221-y

12 Madhok BM Yeluri S Perry SL Hughes TA Jayne DG Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells Br J Cancer 2010 102 1746 1752 20485289 10.1038/sj.bjc.6605701 PMC2883702

13 Cao W Yacoub S Shiverick KT Namiki K Sakai Y Porvasnik S Urbanek C Rosser CJ Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation Prostate 2008 68 1223 1231 18465755 10.1002/pros.20788

14 Saed GM Fletcher NM Jiang ZL Abu-Soud HM Diamond MP Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress Reprod Sci 2011 18 1253 1261 21701041 10.1177/1933719111411731

15 Vella S Conti M Tasso R Cancedda R Pagano A Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells Int J Cancer 2012 130 1484 1493 21557214 10.1002/ijc.26173

16 Fiebiger W Olszewski U Ulsperger E Geissler K Hamilton G In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines Clin Transl Oncol 2011 13 43 49 21239354 10.1007/s12094-011-0615-z

17 Liu D Liu S Jing X Li X Li W Huang Y Necrosis of cervical carcinoma by dichloroacetate released from electrospun polylactide mats Biomaterials 2012 33 4362 4369 22425553 10.1016/j.biomaterials.2012.02.062

18 Wong JY Huggins GS Debidda M Munshi NC De Vivo I Dichloroacetate induces apoptosis in endometrial cancer cells Gynecol Oncol 2008 109 394 402 18423823 10.1016/j.ygyno.2008.01.038 PMC2735772

19 Ishiguro T Ishiguro R Ishiguro M Iwai S Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report Hepatogastroenterology 2012 59 994 996 22580646 10.5754/hge10507

20 Sorokina LV Pyatchanina TV Didenko GV Kaplia AA Khyzhnyak SV The influence of sodium dichloroacetate on the oxidative processes in sarcoma 37 Exp Oncol 2011 33 216 221 22217710

21 Kumar A Kant S Singh SM Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation Chem Biol Interact 2012 199 29 37 22705712 10.1016/j.cbi.2012.06.005

22 Sutendra G Dromparis P Kinnaird A Stenson TH Haromy A Parker JM McMurtry MS Michelakis ED Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer Oncogene 2013 32 1638 1650 22614004 10.1038/onc.2012.198

23 Shahrzad S Lacombe K Adamcic U Minhas K Coomber BL Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia Cancer Lett 2010 297 75 83 20537792 10.1016/j.canlet.2010.04.027

24 Anderson KM Jajeh J Guinan P Rubenstein M In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells Anticancer Res 2009 29 4579 4588 20032407

25 Kankotia S Stacpoole PW Dichloroacetate and cancer: new home for an orphan drug? Biochim Biophys Acta 2014 1846 617 629 25157892 10.1016/j.bbcan.2014.08.005

26 Sun RC Board PG Blackburn AC Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells Mol Cancer 2011 10 142 22093145 10.1186/1476-4598-10-142 PMC3240126

27 Stockwin LH Yu SX Borgel S Hancock C Wolfe TL Phillips LR Hollingshead MG Newton DL Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC Int J Cancer 2010 127 2510 2519 20533281 10.1002/ijc.25499

28 Gang BP Dilda PJ Hogg PJ Blackburn AC Targeting of two aspects of metabolism in breast cancer treatment Cancer Biol Ther 2014 15 1533 1541 25482950 10.4161/15384047.2014.955992 PMC4622508

29 De Grandis D Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review CNS Drugs 2007 21 Suppl 1 39 43; discussion 45-46 17696592 10.2165/00023210-200721001-00006

30 Maestri A De Pasquale Ceratti A Cundari S Zanna C Cortesi E Crinò L A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy Tumori 2005 91 135 138 15948540 10.1177/030089160509100206

31 Evans JD Jacobs TF Evans EW Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy Ann Pharmacother 2008 42 1686 1691 18940920 10.1345/aph.1L201

32 Mijnhout GS Kollen BJ Alkhalaf A Kleefstra N Bilo HJ Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials Int J Endocrinol 2012 2012 456279 22331979 10.1155/2012/456279 PMC3272801

33 Liu F Zhang Y Yang M Liu B Shen YD Jia WP Xiang KS Curative effect of alpha-lipoic acid on peripheral neuropathy in type 2 diabetes: a clinical study Zhonghua Yixue Zazhi 2007 87 2706 2709 18167250

34 Ziegler D Hanefeld M Ruhnau KJ Meissner HP Lobisch M Schütte K Gries FA Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study) Diabetologia 1995 38 1425 1433 8786016 10.1007/BF00400603

35 Winkler G Kempler P Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy Orv Hetil 2010 151 971 981 20519180 10.1556/OH.2010.28898

36 Ang CD Alviar MJ Dans AL Bautista-Velez GG Villaruz-Sulit MV Tan JJ Co HU Bautista MR Roxas AA Vitamin B for treating peripheral neuropathy Cochrane Database Syst Rev 2008 CD004573 18646107 10.1002/14651858.CD004573.pub3 PMC12373429

37 Winkler G Pál B Nagybéganyi E Ory I Porochnavec M Kempler P Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy Arzneimittelforschung 1999 49 220 224 10219465 10.1055/s-0031-1300405

38 Loupakis F Cremolini C Masi G Lonardi S Zagonel V Salvatore L Cortesi E Tomasello G Ronzoni M Spadi R Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer N Engl J Med 2014 371 1609 1618 25337750 10.1056/NEJMoa1403108

39 Hirsch HA Iliopoulos D Tsichlis PN Struhl K Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res 2009 69 7507 7511 19752085 10.1158/0008-5472.CAN-09-2994 PMC2756324

40 Cao A Li Q Yin P Dong Y Shi H Wang L Ji G Xie J Wu D Curcumin induces apoptosis in human gastric carcinoma AGS cells and colon carcinoma HT-29 cells through mitochondrial dysfunction and endoplasmic reticulum stress Apoptosis 2013 18 1391 1402 23881281 10.1007/s10495-013-0871-1

41 Wynn ML Consul N Merajver SD Schnell S Inferring the Effects of Honokiol on the Notch Signaling Pathway in SW480 Colon Cancer Cells Cancer Inform 2014 13 1 12 10.4137/CIN.S14060 PMC4218690 25392689

42 Delaney LM Ho N Morrison J Farias NR Mosser DD Coomber BL Dichloroacetate affects proliferation but not survival of human colorectal cancer cells Apoptosis 2015 20 63 74 25344893 10.1007/s10495-014-1046-4

43 Sun RC Fadia M Dahlstrom JE Parish CR Board PG Blackburn AC Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo Breast Cancer Res Treat 2010 120 253 260 19543830 10.1007/s10549-009-0435-9

44 Sánchez-Aragó M Chamorro M Cuezva JM Selection of cancer cells with repressed mitochondria triggers colon cancer progression Carcinogenesis 2010 31 567 576 20080835 10.1093/carcin/bgq012

45 Tzeng HF Blackburn AC Board PG Anders MW Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate Chem Res Toxicol 2000 13 231 236 10775321 10.1021/tx990175q